Semaglutide 2.4 mg in Patients With Poor Weight-loss
Status:
Not yet recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
A double-blinded, randomised, placebo-controlled trial of semaglutide 3.0 mg/ml in patients
with poor weight-loss following bariatric surgery. The primary aim of this trial is to
determine whether, and the extent to which, 68 weeks of subcutaneous semaglutide 3.0 mg/ml
causes greater percentage weight loss (%WL), reduction in adiposity, improvement in metabolic
and inflammatory indices and health-related quality of life (HRQoL) than placebo, in patients
with poor weight loss following gastric bypass or sleeve gastrectomy.